Brighten your smile with 50% off the advanced teeth whitening system that works in 10 MINUTES: 'I noticed instant results on the first use!'
Designed to whiten teeth by up to eight shades, the system harnesses the power of LED lights to obliterate stains — even older, stubborn ones — and leave your smile vibrant without causing irritation. You can score it today for an epic 50 percent discount, making now the time to renew your commitment to better teeth.
SmilePro Advanced Teeth Whitening Kit
Give your teeth the ultimate smile makeover with this gentle whitening system.
It begins working from the very first use, harnessing the power of blue and red LED light to break down even deep-set stains while protecting your teeth from discomfort.
Safe for even sensitive teeth, the system is now on sale for an incredible 50 percent off and is backed by the brand's 30-day satisfaction guarantee. You won't believe your smile!
Save 50% Shop
Unbelievable results: Shoppers have shared their stunning experiences using SmilePro, which uses both blue and red LED light to break down stains without discomfort
It's an incredible value, as each kit contains 30 treatments. At a price of $70 for the system, this breaks down to approximately $2.33 per treatment — an astonishingly low price for a dental-grade system that is far more convenient to use.
You won't have to wait weeks to see results, either. SmilePro whitens in as little as 10 minutes, instantly giving you a smile makeover while beginning your journey to your ideal whiteness level.
Satisfied users have seen astonishing results in as little as one week, revealing that it's the 'only product that shows results the first time you use it!'
The formula contains an enamel-safe medley of hydrogen peroxide, potassium nitrate to minimize sensitivity, carbomer to oxidize stains, antimicrobial glycerin, and propylene glycol to prevent discomfort when you breathe in dry air.
Sodium hydroxide is also in the mix, and it's critical to preventing bacterial growth (responsible for plaque). Polyvinyl pyrrolidone (PVP) protects your teeth from future stains, while menthol adds a zingy freshness to the formula.
Each SmilePro kit contains three teeth whitening pens (with 10 treatments in each) and a rechargeable, water-resistant LED accelerator light. The light harnesses the power of both blue and red LED, which each play integral roles in treating the teeth.
To use the system, simply apply the formula directly to your teeth via the handy pen applicator. Fit the LED tray into your mouth and activate the light for anywhere from 10 to 30 minutes.
At this stage of treatment, the blue LED light triggers the whitening formula to break down stains. It works quickly, even on deeper stains, to reveal impressive results even after just a single use.
The red LED has a soothing effect on the gums, preventing discomfort to ensure that even those with sensitive teeth can comfortably use the system.
To wrap up your session, simply rinse your mouth. Repeat the process for at least a week, or until the point when you reach your preferred degree of whiteness. It's a simple, clear-cut, and effective way to improve your teeth — and shoppers are thrilled with how well it works.
'Amazing product!' raved one user. 'Noticed instant results on the first use. Have had comments about how white my teeth look.'
'I'm still finishing the treatments but have already had great results after using for just a few consecutive days. I'm really impressed,' shared another.
Why wait another minute? With glowing testimonials like these and a system that is proven to work — not to mention a money-back guarantee — you simply cannot go wrong with the SmilePro Advanced Teeth Whitening Kit for 50 percent off.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
2 hours ago
- The Independent
Scientists identify cause of sea star epidemic along North America's Pacific coast
Scientists have identified a specific bacterium, Vibrio pectenicida, as the cause of the devastating sea star wasting disease that has killed over five billion sea stars off North America's Pacific coast since 2013. The disease, which causes lesions and arm loss, has severely impacted over 20 species, with the sunflower sea star losing approximately 90 percent of its population within five years. The breakthrough, published in Nature Ecology and Evolution, involved meticulously analyzing the coelomic fluid of sea stars, overcoming previous false leads that focused on dead tissue samples. Identifying the bacterium provides a crucial step for intervention, allowing scientists to test remaining sea stars, consider relocation or captive breeding, and investigate natural immunity or probiotic treatments. The recovery of sea star populations is vital for the Pacific ecosystem, as their decline led to an explosion in sea urchins, which subsequently decimated 95 percent of Northern California 's kelp forests.
Reuters
2 hours ago
- Reuters
Vertex's trial failure, scrapped study cloud pain drug push; shares slump
Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of its approved pain drug, sending its shares down 14.4% after the bell. The company (VRTX.O), opens new tab has been diversifying into gene therapies and non-opioid painkillers as it looks to reduce its reliance on cystic fibrosis drugs, a market it dominates. Unlike opioids, which trigger the brain's reward centers, making them an addiction risk, Vertex's drugs block pain signals at the origin, providing a lucrative opportunity for the company. The next-generation non-opioid painkiller, called VX-993, reduced pain by 74.5 points over 48 hours, compared with 50.2 points in the placebo group, but the difference was not statistically significant, Vertex said. The company tested acute pain reduction in patients who had bunionectomy, a surgery to correct deformed bones of the big toe and foot. The drug was found to be generally safe, with most side effects being mild to moderate and no serious problems linked to the painkiller, the company said. Wall Street analysts and investors have been keenly watching the results of the trial, as Vertex seeks to expand beyond Journavx, its non-opioid approved by the U.S. Food and Drug Administration in January for acute pain. Separately, Vertex also said it would not start a study for Journavx to treat a type of nerve pain in the lower back and legs following discussion with the FDA. Leerink Partners analyst David Risinger said Vertex's pain portfolio updates were "disappointing," despite reporting second-quarter results that were above expectations. Vertex plans to prioritize testing of, and later seeking approval for, Journavx to treat a type of nerve pain in diabetic patients. It will also seek to secure approval for other types of nerve pain, the company said in its earnings press release.
The Independent
2 hours ago
- The Independent
Colorectal cancer rates in the US have increased ‘steeply', research finds
Research indicates a steep rise in colorectal cancer rates among younger adults in the U.S., with a 50 percent relative increase observed between 2021 and 2022. The recommended screening age was lowered from 50 to 45 in 2021 to encourage earlier detection, as early onset cases have nearly doubled in young adults under 55 over the past decade. Colorectal cancer is the third leading cause of cancer deaths in the U.S., with over 154,000 new cases projected for this year. While theories such as poor nutritional health and gut toxins are being explored, researchers have not yet identified a definitive cause for the surge in cases. Experts predict that by 2030, colorectal cancer could become the leading cause of cancer death for individuals under 50, highlighting the need for increased public awareness and screening.
